Aurinia Pharmaceuticals Inc. (AUPH) Stock Score, Valuation & Financial Research
Aurinia Pharmaceuticals Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 84/100.
Quick answer for AUPH
Aurinia Pharmaceuticals Inc. currently has a Wall Street Score of 84/100. The stored market price is $16.1. Its financial score is 41/100. Its valuation score is 100/100. The latest WSS change is +1.5 points. These figures are a research snapshot, not a buy or sell recommendation.
What Aurinia Pharmaceuticals Inc. does
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
AUPH financial snapshot
- Wall Street Score:
- 84/100
- Current price:
- $16.1
- Market capitalization:
- $2.07B
- Revenue:
- $311.5M
- Net income:
- $314.1M
- Free cash flow:
- $135.4M
- Cash:
- $179.8M
- Total debt:
- $60.4M
- EPS:
- 2.36
- P/E ratio:
- 6.8x
- Financial score:
- 41/100
- Valuation score:
- 100/100
- Revenue score:
- 67/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $135.4M, showing positive cash generation.
- The balance sheet shows $179.8M of cash versus $60.4M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +1.5 points: AUPH increased 1.5 points because Valuation improved by 15 points.
What the numbers mean
Its current valuation score is 100/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 41/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research AUPH
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.